CG Invites 
Welcome,         Profile    Billing    Logout  
 6 Products   6 Diseases   6 Products   997 Trials   3103 News 


«12...40414243444546474849505152»
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Trial completion date, Trial initiation date, PD(L)-1 Biomarker, IO biomarker:  A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC (clinicaltrials.gov) -  Sep 11, 2018   
    P2,  N=120, Recruiting, 
    Active, not recruiting --> Recruiting | Trial completion date: Oct 2018 --> Jun 2019 | Initiation date: Jan 2017 --> Jun 2017
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Trial primary completion date:  APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) -  Sep 5, 2018   
    P2,  N=43, Active, not recruiting, 
    Trial completion date: Jun 2019 --> Dec 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2019 --> Sep 2018
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment change, Trial completion date, Trial primary completion date:  A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC (clinicaltrials.gov) -  Jul 26, 2018   
    P2,  N=152, Recruiting, 
    Not yet recruiting --> Recruiting N=36 --> 152 | Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Dec 2017 --> Nov 2018
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Phase classification, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC (clinicaltrials.gov) -  Apr 13, 2018   
    P2,  N=58, Recruiting, 
    Initiation date: Feb 2018 --> Jun 2018 Phase classification: P1/2 --> P2 | Trial completion date: Dec 2020 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2019
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC (clinicaltrials.gov) -  Mar 20, 2018   
    P3,  N=412, Recruiting, 
    Phase classification: P1/2 --> P2 | Trial completion date: Dec 2020 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2019 Trial completion date: Jun 2021 --> Nov 2019 | Trial primary completion date: Dec 2020 --> May 2019
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients (clinicaltrials.gov) -  Mar 12, 2018   
    P1,  N=49, Active, not recruiting, 
    Trial completion date: Jun 2021 --> Nov 2019 | Trial primary completion date: Dec 2020 --> May 2019 Recruiting --> Active, not recruiting | N=24 --> 49 | Trial completion date: Aug 2018 --> May 2019 | Trial primary completion date: Dec 2017 --> Nov 2018
  • ||||||||||  SHR7390 / Jiangsu Hengrui Pharma, AiRuiKa (camrelizumab) / HLB Bio Group, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Enrollment open, Trial initiation date:  SHR7390-I-102-AST: The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Feb 28, 2018   
    P1,  N=60, Recruiting, 
    Recruiting --> Active, not recruiting | N=24 --> 49 | Trial completion date: Aug 2018 --> May 2019 | Trial primary completion date: Dec 2017 --> Nov 2018 Not yet recruiting --> Recruiting | Initiation date: Jul 2017 --> Jul 2017
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker:  A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) (clinicaltrials.gov) -  Feb 7, 2018   
    P2,  N=118, Recruiting, 
    N=90 --> 60 Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2018 --> Dec 2018 | Trial completion date: Aug 2018 --> Jun 2019 | Initiation date: Mar 2017 --> Mar 2017
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment change:  Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer (clinicaltrials.gov) -  Jan 18, 2018   
    P1/2,  N=90, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2018 --> Dec 2018 | Trial completion date: Aug 2018 --> Jun 2019 | Initiation date: Mar 2017 --> Mar 2017 N=30 --> 90
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Trial initiation date, Trial primary completion date:  APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) -  Jan 3, 2018   
    P2,  N=37, Recruiting, 
    N=30 --> 90 Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jun 2019 --> Sep 2019
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Phase classification:  A Study to Evaluate SHR-1210 in Subjects With Advanced HCC (clinicaltrials.gov) -  Dec 27, 2017   
    P2,  N=220, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jun 2019 --> Sep 2019 Recruiting --> Active, not recruiting | Phase classification: P2/3 --> P2
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment change:  A Study to Evaluate SHR-1210 in Subjects With Advanced HCC (clinicaltrials.gov) -  Sep 26, 2017   
    P2/3,  N=220, Recruiting, 
    Not yet recruiting --> Recruiting N=60 --> 220